Kornimate/medical-research-clean huggingface dataset:
motor task performance under visual and auditory feedback post stroke: a randomized crossover trial

Conditions: Ischemic Stroke; Upper Extremity Paresis

Summary: the study was designed to evaluate the impact of a novel kinematic biofeedback system - sword - in the motor performance of patients after stroke. the sword system combines inertial motion trackers and a mobile app, allowing digitization of patient motion and providing real-time audiovisual biofeedback. the investigators hypothesize that the biofeedback feedback provided by the sword system improves patient performance, defined as an increase in the number of correct movements. the design of the study is a cross-over randomized clinical trial. patients will be randomized into two groups. both will perform two separate sessions consisting of one exercise - shoulder flexion with elbow flexion at 90 degrees - for 4 minutes in both experimental settings: with and without biofeedback. group 1 will perform the exercise with biofeedback first and without biofeedback after, with an interval \>24h. group 2 will perform the exercise in the opposite order. the sword system will be used to record movement data in both sessions, but the feedback was only active in one of them.


Eligibility criteria:
inclusion criteria: * clinical symptoms and signs and ct or mri findings compatible with a lesion in the territory of the medial cerebral artery; * persistent motor deficit on the upper limb but not plegia with a score between 0 and 2 on item 5b of the national institute of health stroke scale (nihss) * more than 2 weeks after stroke onset; * the ability to sit comfortably for more than 10 minutes and perform two-step commands exclusion criteria: * no detectable motor deficits at baseline assessment; * severe aphasia; * clinical dementia or mini mental state examination (mmse) below cutoff; * other cognitive or psychiatric comorbidity that impaired communication or compliance with the tasks; * severe respiratory or cardiac condition incompatible with more than 5 minutes of continuous mild exercise in a sitting position; * pain or deformity that limited upper limb movement on the affected side.
improving the cognitive accessibility of self-reports for people with id

Conditions: Mild Intellectual Disability; Borderline Intellectual Functioning

Summary: in the proposed study, the investigators aim to investigate whether the existing abas-3 self-report questionnaire is suitable to be completed meaningfully by individuals who are perceived as having mild intellectual disability (55\<iq\<85) based on cognitive impairment. based on the participants' experiences and researchers' expertise, the investigators develop a 'more inclusive' self-report version. the investigators then look at the extent to which participants indicate that they understand this version better, based on user experiences and limited psychometric research. in doing so, the investigators also compare the outcomes of the self-report and informant-report variant.


Eligibility criteria:
inclusion criteria: * age 18 years or older * last known total intelligence quotient (tiq) 55 - 85 * receiving support from a care organization for persons with id. * a care worker who knows the participant for at least a year and knows him well enough tot complete the informant version of the abas-3 is available. exclusion criteria: • severe physical or sensory impairment limiting ability to participate.

Keywords: self-report questionnaires inclusive diagnostics easy-read language adaptive functioning
study of single dose daptomycin in pediatric patients with gram-positive infection for which they are receiving standard antibiotics

Conditions: Gram-positive Bacterial Infections

Summary: the purpose of this study is to evaluate the pharmacokinetics of a single dose of daptomycin in patients aged 2-17 years old who have a suspected or proven gram-positive infection for which they are receiving standard antibiotic therapy. the tolerability of a single dose of daptomycin in these patients will also be assessed.


Eligibility criteria:
inclusion criteria: * 2-17 years old * suspected or diagnosed gram-positive infection for which the patient is receiving standard antibiotic therapy * clinically stable with no evidence of hemodynamic instability in the 72 hour window prior to enrollment, and no history or evidence of renal or hepatic compromise, or clinically significant alterations in fluid/electrolyte homeostasis * creatinine clearance (clcr) ≥ 80 ml/min/1.73 m2 as determined by the schwartz equation * creatine phosphokinase (cpk) levels within normal limits exclusion criteria: * known allergy to daptomycin * history of clinically significant cardiovascular, renal, hepatic, pulmonary (well-controlled asthma is acceptable), gastrointestinal, endocrine, hematologic, or autoimmune disease * pneumonia as sole gram-positive infection * use of hmg-coa reductase inhibitors or other systemic anti-hyperlipidemic agents within 7 days prior to study drug administration and expected use through 3 days post-dose * clinically significant abnormal laboratory test results (including electrocardiograms \[ecgs\]), as determined by investigator * body mass index (bmi) that is outside of the 5th to 95th percentile for age * history (personal or 1st degree relative) of clinically significant muscular disease, nervous system, seizure or psychiatric disorder * expected intramuscular (im) injection within 3 days following dosing * expected surgical procedure(s) within 3 days following dosing * unexplained muscular weakness * rhabdomyolysis, myositis or septic shock

Keywords: gram-positive infection
clinical trial to assess the efficacy and safety of yyd601 in the treatment of esophageal reflux disease (erd)

Conditions: Erosive Esophagitis

Summary: a randomized, double-blind, double-dummy, active comparator, multi-centers, non-inferiority design clinical trial to assess the efficacy and safety of yyd601 in erd patients (phase 3).

this phase 3 clinical trial is designed as randomized, active-comparator, double-dummy, multi-center for erd patients, who take yyd601 40mg or nexium 40mg for 8 weeks. each part is assessed by 'la grade' measured through the endoscopy, target goal is to confirm the non-inferiority of yyd601 40mg to nexium 40mg.

Eligibility criteria:
inclusion criteria: * a man or woman over 20 years old less than 70 years old. * a man or woman who has experienced symptom (heartburn and acid regurgitation) within 7 days before visit 1, meet below 1) or 2) criteria, who has been made diagnosis as erosive esophagitis(la grade a\~d) measured through the endoscopy which is carried out within (-2w±d2) \* symptom (heartburn and acid regurgitation) is confirmed by rdq. 1. experienced above 2 days in 1 week, heartburn of acid regurgitation above the weakness. 2. experienced above 1 day in 1 week, heartburn of acid regurgitation above the middle. * a man or woman who has a full understanding of this clinical trial through the detailed explanation, agree in writing to participate in this trial. exclusion criteria: * who has hyper sensitivity reaction about other drugs, ingredients, components of investigator product or compound of benzimidazole. * who has nerd * who get a diagnosis as a ibs within the last 3 months. * who have taken gastric acid secretion inhibitors including ppis within 2 weeks before the endoscopy. * who have taken drugs about reflux esophagitis (h₂-receptor inhibitor (h2ra) prostaglandin(pg), antacid, prokinetic acid etc.) above 2 times as an usual dose. (\* refer to the concomitant medication in text.) * who has been experienced the disease affecting the esophagus(eosinophilic esophagitis, esophageal varices, cirrhosis, virus or fungal infection, esophageal stricture, primary esophageal motility disorder and gastrointestinal bleeding). or who has a history of radio therapeutics, freeze treatment about the esophagus. * who has clinically significant abnormal result of ecg. * abnormal result of major arrhythmia, multifocal pvs, 2 av-blcok etc. * who has the schatzki near the les(lower esophageal sphincter) except the barret's esophagus.
endoscopic saphenous vein harvest for coronary artery bypass grafting

Conditions: Coronary Artery Disease

Summary: although the long saphenous vein remains the most commonly used conduit in coronary revascularization, traditional open vein harvest may lead to significantly impaired wound healing and post-operative pain. to this end, endoscopic saphenous vein harvesting techniques have been shown to reduce post-operative morbidity. studies have shown that endothelial integrity and luminal nitric oxide synthase (nos) are better preserved with novel "no-touch" techniques; however, the effect and the associated mechanism of endoscopic vein harvest on endothelial integrity and function remain unknown. therefore, in the present proposal, we will collect the saphenous vein segements immediately after harvesting, reperfusion, and grafting, and then use enzyme-linked immunosorbant assay (elisa), immunohistochemical staining (ihc), and real-time polymerase chain reaction (rt-pcr) to detect the expression and distribution of endothelial nos (enos), endothelin-1 (et-1), vascular cell adhesion molecule-1 (vcam-1), intracellular adhesion molecule-1 (icam-1), and platelet endothelial cell adhesion molecule-1(pecam-1) at protein and rna levels in the endothelium of saphenous veins. the major aim of this study is to elucidate the effect and mechanism of endoscopic saphenous vein harvesting on endothelial properties as compare to conventional open vein harvest technique.


Eligibility criteria:
inclusion criteria: * patient with coronary artery disease underwent coronary artery bypass grafting in our hospital exclusion criteria: * no

Keywords: coronary artery bypass grafting endoscopic vein harvest saphenous vein endothelial cells enos et-1
defecation postures for functional consumption

Conditions: Constipation

Summary: whether functional consumption is influenced by defecation postures is unclear. the investigators investigated effects of defecation postures on functional consumption.

constipation is a chronic problem in many patients all over the world. in some groups of patients such as the elderly, constipation is a significant health care problem. a prospective study was performed at 3 hospitals in china. the included patients were functional consumption patients with defecation sitting on a standard-sized toilet. patients received standard functional consumption treatment according to the guideline and were randomly assigned to groups that using a squatting pan or a standard-sized toilet.

Eligibility criteria:
inclusion criteria: * subject has functional constipation * subject does not receive other treatments exclusion criteria: * history of heart cerebrovascular disease * history of other types of constipation * pregnant, trying to become pregnant or breast feeding * age\ 70-year
mobile health fitness program for adolescent and young adult childhood cancer survivors

Conditions: Survivorship; Fatigue

Summary: this clinical trial studies a mobile health fitness program for adolescent and young adult childhood cancer survivors. adolescent and young adult childhood cancer survivors are at risk to have negative late effects from treatment and to develop chronic health conditions. a sedentary lifestyle may increase the risk of cardiovascular disease, osteoporosis, and early mortality. physical activity reduces the risk for cardiovascular disease and early mortality, improves cardiorespiratory fitness, muscular fitness, bone health, and body composition, and it is also positively associated with quality of life. programs and technologies that promote physical activity are important because health behaviors adopted by adolescent and young adult childhood cancer survivors are likely to continue into adulthood. a mobile health fitness application may motivate adolescent and young adult childhood cancer survivors to engage and maintain physical activity.

primary objectives: i. evaluate the feasibility of the technology-enhanced (electronic accelerometer + app + 8 weekly group sessions) fitness program in a pilot randomized clinical trial. secondary objectives: i. determine the effectiveness of the technology-enhanced fitness program on participants' cardiorespiratory fitness and muscular fitness. ii. examine the effects of the program on secondary outcomes of health related quality of life (hrqol) and fatigue. outline: participants are randomized to 1 of 2 arms. arm i (intervention): participants attend 8 group meetings weekly, wear an electronic accelerometer, engage in private social support messaging within the app and facebook private groups, and then use the mobile app for 4 weeks without in-person groups. arm ii (waitlist control \[wlc\]): after the 6 month assessment, participants receive the fitsurvivor intervention as in arm i.

Eligibility criteria:
inclusion criteria: * any diagnosis of cancer prior to age 21 * off treatment for at least 6 months * for patients \ = 18 must give informed consent exclusion criteria: * any medical contraindication to exercise according to a physician or physician's designee * non-english speaking * current physical activity level exceeding centers for disease control and prevention (cdc) guidelines for activity (60 min of moderate-vigorous exercise/day for 5+ days/week (wk) including 3+ days of vigorous intensity activities and muscle-strengthening exercises on 3+ days/wk and bone strengthening exercises on 3+ days/wk for children \ = 18); the cdc guidelines are used to determine exercise prescription in our intervention; individuals already exceeding the guidelines would be unlikely to benefit from participating * significant developmental delay per patient, parent, or physician report * pregnant (per patient report); if participant becomes pregnant during the course of the study, she will be removed from further participation
molecular diagnostics of bacterial infections and antibiotic resistance in blood samples and rectal swabs using real time pcr-ares pcr methods

Conditions: Drug Resistant Bacterial Infection

Summary: experimental study without drug and device, on pseudo-anonymized samples archived at the tropica biobank. the objective is to evaluate the performance for the identification of microorganisms in blood samples and rectal swabs of real time pcr assays for the targets: kpc, vim, imp, ndm, acinetobacter oxa, oxa48, mcr. the evaluations will be carried out taking into consideration the data obtained from the diagnostic routine at the ditm.


Eligibility criteria:
inclusion criteria: * samples of patients for whom blood culture and multi drug resistant (mdr) surveillance tests were carried out in rectal swabs at the irccs sacro cuore don calabria hospital * samples for which the information and consent to the conservation of biological samples for research purposes at the tropica biobank has been signed exclusion criteria: * absence of data relating to positivity or negativity to the germs of interest * absence of stored residual material * absence of information and consent to the conservation of biological samples for signed research purposes
increased gut permeability to lipopolysaccharides (lps) in parkinson's disease

Conditions: Parkinson's Disease; Multiple System Atrophy

Summary: the gut may be a portal of entry for agents that cause or contribute to the causes of parkinson's disease (pd). the investigators are studying changes in the normal population of gut flora and in intestinal permeability and their associations with early pd.

clinical and pathological data suggest parkinson's disease (pd) may result from an inflammatory process beginning in the intestinal wall that initiates alpha-synuclein aggregation, which then spreads from neuron to neuron, reaching the central nervous system. bacteria living within the intestinal tract produce lipopolysaccharide endotoxin, a toxin known to induce parkinsonism in animal models. we hypothesize that exposure to lps, either from excessive production or excessive absorption may be the cause of this inflammation. this study aims to: (1) describe differences in the population of gut bacteria in pd compared to control subjects; (2) assess leakiness of the gut wall by differential absorption of non-absorbable sugars; (3) measure plasma levels of endotoxin and inflammation; and (4) study characteristic pd pathology and evidence of inflammation in biopsy samples of the colon obtained by sigmoidoscopy.

Eligibility criteria:
inclusion criteria--parkinson's disease: * clinically diagnosed parkinson's disease * hoehn \& yahr stage 1-2.5 * no symptomatic treatment of parkinson's disease symptoms inclusion criteria--multiple system atrophy * clinically diagnosed multiple system atrophy. inclusion criteria--control subjects: * no diagnosis of parkinson's disease and no signs of parkinson's disease on screening neurological examination exclusion criteria: * secondary or atypical parkinsonism other than multiple system atrophy * occupation or medical treatment known to influence intestinal flora * organic gastrointestinal disease other than hiatal hernia or hemorrhoids; history of gastrointestinal surgery other than remote appendectomy or cholecystectomy. * acute or chronic medical illness that would confound study results. * coagulopathy or use of anticoagulant medications (including aspirin). * chronic use of diuretics

Keywords: lipopolysaccharides etiology inflammation colonic bacteria intestinal permeability
non invasive measurements of intracranial pressure in patients with malignant glioma

Conditions: Glioma

Summary: in patients at risk of increased intracranial pressure (icp), icp measurements require invasive transducers, usually with insertion of a catheter into the cranium, or through a spinal tap. these invasive modalities involve risks and pain and they can be done only in specialized care units, with a high associated cost. a novel method for detecting changes in icp has developed recently. the auditory hair cells emit sounds and electric signals in response to sound, which can be easily detected and measured non-invasively with the help of a microphone probe placed in the external ear canal or regular electrodes. indeed, the cochlear aqueduct connects the cerebrospinal fluid (csf) spaces to the inner ear in such a way that icp and inner-ear fluid pressure equalize within seconds. a symptom of intracranial pressure (icp) was observed in glioma patient due to a combination of causes: the inflammatory reaction around the tumor, the mass effect of the tumor, secondary vascular changes, a change in the flow of csf. the evaluation of intracranial hypertension by increased icp (invasive) is not used in the monitoring of intracranial tumors. it is then detected by using routine clinical signs, in combination with a standard imaging method (mri), but still subjective. the measurement of noninvasive icp could allow earlier detection of relapse, and evaluate whether the increase in icp precedes tumor clinical worsening and / or imaging.


Eligibility criteria:
inclusion criteria: * patients with malignant glioma who underwent a biopsy or a partial surgery of this tumor and a radiotherapy and/or chemotherapy treatment. * valid tympanometry test at least for one ear * between 18 and 65 years of age * cochlear response useful at least for an ear which has validate the tympanometry test * written informed consent reviewed and signed by patient * affiliation to a social security scheme exclusion criteria: * patients who underwent a complete resection of their malignant glioma * invalid tympanometry test for the both ears * collect of cochlear responses impossible for the ear or both ear which validate the tympanometry test * patient refusal after enlightened information

Keywords: intracranial pressure
study of adalimumab (humira®) in patients with moderate to severe psoriasis (ps) in spain (promise)

Conditions: Moderate-to-severe Chronic Plaque Psoriasis

Summary: the purpose of this study is to evaluate the effectiveness and safety of adalimumab as used in routine clinical practice in adult patients with moderate to severe chronic plaque psoriasis in spain.

promise is a 2 year post-authorization study of patients taking adalimumab for psoriasis. patients who volunteer to participate will be asked to provide information about their medical history and experiences with adalimumab. no study specific testing will be performed. patients will be asked to provide data on their experiences with adalimumab approximately every 6 months, or as determined by the study doctor. no drug will be provided as a result of participation in the registry. all treatment decisions are independent of participation in the registry. a total of 547 subjects were enrolled: 532 in the itt population were analyzed for efficacy (excluding 15 for lack of follow-up visits (n=8), non-fulfillment of the criteria of moderate to severe ps (n=6) and failure to initiate treatment at the baseline visit (n=1)); 542 were analyzed for safety (excluding 5 due to lack of evaluable safety data).

Eligibility criteria:
inclusion criteria: * patient 18 years of age or older. * patient diagnosed with moderate to severe chronic plaque ps beginning treatment with adalimumab in accordance with the authorized conditions of use. * patient gives informed consent in writing. exclusion criteria: * patients who cannot be treated in accordance with the local product label * patient participating or going to participate in a clinical trial during the study follow-up * patient with difficulties for adequately reading, understanding and completing a questionnaire

Keywords: moderate psoriasis psoriasis severe psoriasis adalimumab effectiveness safety clinical practice
mrd-associated non-intensive but non-interruptive treatment of ph-negative acute lymphoblastic leukemia adult patients

Conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma

Summary: non-intensive but non-interruptive treatment based on previously study rall-2016 of adult ph-negative acute lymphoblastic leukemia: no high-dose methotrexate (mtx) and high-dose cytarabine (ara-c) consolidation blocks, l-asparaginaseis scheduled for 1 year of treatment, 21 intrathecal injections through the whole treament, t-all patients in complete remission (cr) with mrd-positive status after 2nd induction receive consolidation 1-3 with venetoclax (56 days), and b-all patients in complete remission (cr) with mrd-positive status after 2nd induction receive 1 consolidation with blinatumomab. after that consolidation bone samples are collected and tested for mrd and patients will continue therapy by protocol without hsct if mrd-negative (by flow cytometry by aberrant immunophenotype in a centralized lab) status was achieved.

* 7 days prednisolone prephase * 8 weeks induction with de-escalation of induction chemotherapy: 3 instead of 4 dauno/vncr pulses, 1. instead of 2 cph injections during induction, 2. instead of 4 ara-c blocks, distribution of of l-asp injections through all phases * after cr achievement t-cell all and b-all patients are being study mrd (by fcm) mrd-positive patients with t-all will receive 1-3 consolidation with venetoclax (400 mg/d), and b-all patients will receive1 additional consolidation by blinatumomab * non-interruptive 5 consolidation phases with dose modification according to wbc and platelets count after cr achievement. rotation of consolidation is permitted * 2 years maintenance for all patients * 21 tit through the whole treatment with higher intensity during induction\|consolidation * centralized mrd monitoring at +70 d, + 133 d, + 190 days; before and after allo-hsct * allo-hsct is planned only for very high risk patients (11q23 all, mrd positivity after target therapy, etp t-all)

Eligibility criteria:
inclusion criteria: • age 18-55 years old of patient, - clinical diagnosis of non-treated ph-negative all exclusion criteria: • age more than 55 years old, * clinical diagnosis of ph-positive all * clinical diagnosis of relapsed/refractory all,